Italia markets closed

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,7000-0,1000 (-12,50%)
Alla chiusura: 05:07PM BST
Schermo intero
Chiusura precedente0,8000
Aperto0,7000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,7000 - 0,7000
Intervallo di 52 settimane0,7000 - 0,7000
Volume600
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)-0,44
Rapporto PE (ttm)N/D
EPS (ttm)-0,4040
Prossima data utili09 nov 2022 - 14 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

    Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ETOCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune di

  • GlobeNewswire

    AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D. Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24th Annual Global Investment Conference

  • GlobeNewswire

    AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

    OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present a